CD40 and glioblastoma: Furthermore, immune-cold tumors also encouraged successful therapeutic outcomes for both DC vaccines, where ovarian tumors responded even better to an autologous DC vaccine than hot tumors,70 and CD40 and TLR agonists, which induced clinical responses in notoriously cold tumors such as glioblastoma, PDAC, and MSS-CRC.66